For individuals with type 2 diabetes (T2D) who are initiating oral glucose-lowering monotherapy, a history of clinically diagnosed depression is associated with earlier treatment intensification, such as adding medication or switching to a new drug class, and insulin initiation, as shown in a retrospective study.